Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

***Medical Lab science review- Robert Harr 4th > Hematology- Inhibitors, Thrombotic Disorders, and Anticoagulant Drugs > Flashcards

Hematology- Inhibitors, Thrombotic Disorders, and Anticoagulant Drugs Flashcards

You may prefer our related Brainscape-certified flashcards:
Biology 101 flashcards USMLE® Step 1 flashcards
1
Q
  1. Which characteristic describes antithrombin (AT)?
    A. It is synthesized in megakaryocytes
    B. It is activated by protein C
    C. It is a cofactor of heparin
    D. It is a pathological inhibitor of coagulation
A

C. It is a cofactor of heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
  1. Which laboratory test is affected by heparin
    therapy?
    A. Thrombin time
    B. Fibrinogen assay
    C. Protein C assay
    D. Protein S assay
A

A. Thrombin time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
  1. An abnormal APTT caused by a pathological
    circulating anticoagulant is:
    A. Corrected with factor VIII–deficient plasma
    B. Corrected with factor IX–deficient plasma
    C. Corrected with normal plasma
    D. Not corrected with normal plasma
A

D. Not corrected with normal plasma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q
  1. The lupus anticoagulant affects which of the
    following tests?
    A. Factor VIII assay
    B. Factor IX assay
    C. VWF assay
    D. Phospholipid-dependent assays
A

D. Phospholipid-dependent assays

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q
  1. Which statement about Coumadin (warfarin) is
    accurate?
    A. It is a vitamin B antagonist
    B. It is not recommended for pregnant and
    lactating women
    C. It needs antithrombin as a cofactor
    D. APTT test is used to monitor its dosage
A

B. It is not recommended for pregnant and
lactating women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q
  1. Which statement regarding protein C is correct?
    A. It is a vitamin K–independent zymogen
    B. It is activated by fibrinogen
    C. It activates cofactors V and VIII
    D. Its activity is enhanced by protein S
A

D. Its activity is enhanced by protein S

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
  1. Which of the following is an appropriate screening
    test for the diagnosis of lupus anticoagulant?
    A. Thrombin time test
    B. Diluted Russell’s viper venom test (DRVVT)
    C. D-dimer test
    D. FDP test
A

B. Diluted Russell’s viper venom test (DRVVT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q
  1. Which of the following is most commonly
    associated with activated protein C resistance
    (APCR)?
    A. Bleeding
    B. Thrombosis
    C. Epistaxis
    D. Menorrhagia
A

B. Thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q
  1. A 50-year-old man has been on heparin for the
    past 7 days. Which combination of the tests is
    expected to be abnormal?
    A. PT and APTT only
    B. APTT, TT only
    C. APTT, TT, fibrinogen assay
    D. PT, APTT, TT
A

D. PT, APTT, TT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
  1. Which of the following drugs inhibits ADP
    mediated platelet aggregation?
    A. Heparin
    B. Warfarin
    C. Aspirin
    D. Prasugrel
A

D. Prasugrel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q
  1. Thrombin-thrombomodulin complex is necessary
    for activation of:
    A. Protein C
    B. Antithrombin
    C. Protein S
    D. Factors V and VIII
A

A. Protein C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q
  1. What test is used to monitor heparin therapy?
    A. INR
    B. APTT
    C. TT
    D. PT
A

B. APTT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q
  1. What test is commonly used to monitor warfarin
    therapy?
    A. INR
    B. APTT
    C. TT
    D. Ecarin time
A

A. INR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q
  1. What clotting factors (cofactors) are inhibited by
    protein S?
    A. V and X
    B. Va and VIIIa
    C. VIII and IX
    D. VIII and X
A

B. Va and VIIIa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
  1. Which drug promotes fibrinolysis?
    A. Warfarin
    B. Heparin
    C. Urokinase
    D. Aspirin
A

C. Urokinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q
  1. Diagnosis of lupus anticoagulant is confirmed by
    which of the following criteria?
    A. Decreased APTT
    B. Correction of the APPT by mixing studies
    C. Neutralization of the antibody by high
    concentration of platelets
    D. Confirmation that abnormal coagulation tests are
    time and temperature dependent
A

C. Neutralization of the antibody by high
concentration of platelets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q
  1. Which of the following abnormalities is consistent
    with the presence of lupus anticoagulant?
    A. Decreased APTT/bleeding complications
    B. Prolonged APTT/thrombosis
    C. Prolonged APTT/thrombocytosis
    D. Thrombocytosis/thrombosis
A

B. Prolonged APTT/thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q
  1. Which of the following is a characteristic of low
    molecular weight heparin (LMWH)?
    A. Generally requires monitoring
    B. Specifically acts on factor Va
    C. Has a longer half-life than unfractionated
    heparin
    D. Can be used as a fibrinolytic agent
A

C. Has a longer half-life than unfractionated
heparin

19
Q
  1. Which of the following tests is most likely to be
    abnormal in patients taking aspirin?
    A. Platelet morphology
    B. Platelet count
    C. Bleeding time
    D. Prothrombin time
A

C. Bleeding time

20
Q
  1. Which of the following is associated with
    antithrombin deficiency?
    A. Thrombocytosis
    B. Thrombosis
    C. Thrombocytopenia
    D. Bleeding
A

B. Thrombosis

21
Q
  1. Which of the following may be associated with
    thrombotic events?
    A. Decreased protein C
    B. Increased fibrinolysis
    C. Afibrinogenemia
    D. ITP
A

A. Decreased protein C

22
Q
  1. Aspirin resistance may be associated with:
    A. Bleeding
    B. Factor VIII deficiency
    C. Thrombosis
    D. Thrombocytosis
A

C. Thrombosis

23
Q
  1. A prolonged thrombin time is indicative of which
    of the following antithrombotic therapies?
    A. Prasugrel
    B. Clopidogrel
    C. Aspirin
    D. Heparin
A

D. Heparin

24
Q
  1. Screening tests for thrombophilia should be
    performed on:
    A. All pregnant women because of the thrombotic
    risk
    B. Patients with a negative family history
    C. Patients with thrombotic events occurring at a
    young age
    D. Patients who are receiving anticoagulant therapy
A

C. Patients with thrombotic events occurring at a
young age

25
Q
  1. Prothrombin G20210A is characterized by which
    of the following causes and conditions?
    A. Single mutation of prothrombin molecule/
    bleeding
    B. Single mutation of prothrombin molecule/
    thrombosis
    C. Decreased levels of prothrombin in plasma/
    thrombosis
    D. Increased levels of prothrombin in plasma/
    bleeding
A

B. Single mutation of prothrombin molecule/
thrombosis

26
Q
  1. Factor V Leiden promotes thrombosis by
    preventing:
    A. Deactivation of factor Va
    B. Activation of factor V
    C. Activation of protein C
    D. Activation of protein S
A

A. Deactivation of factor Va

27
Q
  1. What is the approximate incidence of
    antiphospholipid antibodies in the general
    population?
    A. <1%
    B. 2%
    C. 10%
    D. 20%
A

B. 2%

28
Q
  1. Which of the following laboratory tests is helpful
    in the diagnosis of aspirin resistance?
    A. APTT
    B. PT
    C. Platelet count and morphology
    D. Platelet aggregation
A

D. Platelet aggregation

29
Q
  1. Which of the following complications may occur
    as a result of decreased tissue factor pathway
    inhibitor (TFPI)?
    A. Increased hemorrhagic episodes
    B. Increased thrombotic risk
    C. Impaired platelet plug formation
    D. Immune thrombocytopenia
A

B. Increased thrombotic risk

30
Q
  1. Factor VIII inhibitors occur in ____________ of
    patients with factor VIII deficiency?
    A. 40%–50%
    B. 30%–40%
    C. 25%–30%
    D. 10%–20%
A

D. 10%–20%

31
Q
  1. Which therapy and resulting mode of action are
    appropriate for the treatment of a patient with a
    high titer of factor VIII inhibitors?
    A. Factor VIII concentrate to neutralize the
    antibodies
    B. Recombinant factor VIIa (rVIIa) to activate
    factor X
    C. Factor X concentrate to activate the common
    pathway
    D. Fresh frozen plasma to replace factor VIII
A

B. Recombinant factor VIIa (rVIIa) to activate
factor X

32
Q
  1. The Bethesda assay is used for which
    determination?
    A. Lupus anticoagulant titer
    B. Factor VIII inhibitor titer
    C. Factor V Leiden titer
    D. Protein S deficiency
A

B. Factor VIII inhibitor titer

33
Q
  1. Hyperhomocysteinemia may be a risk factor for:
    A. Bleeding
    B. Thrombocythemia
    C. Thrombosis
    D. Thrombocytopenia
A

C. Thrombosis

34
Q
  1. Which drug may be associated with deep venous
    thrombosis (DVT)?
    A. Aspirin
    B. tPA
    C. Oral contraceptives
    D. Plavix (clopidogrel)
A

C. Oral contraceptives

35
Q
  1. Argatroban may be used as an anticoagulant drug
    in patients with:
    A. DVT
    B. Hemorrhage
    C. TTP
    D. Thrombocytosis
A

A. DVT

36
Q
  1. Heparin-induced thrombocytopenia (HIT)
    results from:
    A. Antibodies to heparin
    B. Antibodies to platelets
    C. Antibodies to PF4
    D. Antibodies to heparin-PF4 complex
A

D. Antibodies to heparin-PF4 complex

37
Q
  1. Which laboratory test is used to screen for
    activated protein C resistance?
    A. Mixing studies with normal plasma
    B. Mixing studies with factor-deficient plasma
    C. Modified APTT with and without activated
    protein C
    D. Modified PT with and without activated
    protein C
A

C. Modified APTT with and without activated
protein C

38
Q
  1. Ecarin clotting time may be used to monitor:
    A. Heparin therapy
    B. Warfarin therapy
    C. Fibrinolytic therapy
    D. Hirudin therapy
A

D. Hirudin therapy

39
Q
  1. Which of the following may interfere with the
    activated protein C resistance (APCR) screening
    test?
    A. Lupus anticoagulant
    B. Protein C deficiency
    C. Antithrombin deficiency
    D. Protein S deficiency
A

A. Lupus anticoagulant

40
Q
  1. Thrombophilia may be associated with which
    of the following disorders?
    A. Afibrinogenemia
    B. Hypofibrinogenemia
    C. Factor VIII inhibitor
    D. Hyperfibrinogenemia
A

D. Hyperfibrinogenemia

41
Q
  1. Which of the following anticoagulant drugs can be
    used in patients with HIT?
    A. Warfarin
    B. Heparin
    C. Aspirin
    D. Lepirudin
A

D. Lepirudin

42
Q
  1. Which of the following is the preferred method
    to monitor heparin therapy at the point of care
    during cardiac surgery?
    A. APTT
    B. Activated clotting time test (ACT)
    C. PT
    D. TT
A

B. Activated clotting time test (ACT)

43
Q
  1. Mrs. Smith has the following laboratory results,
    and no bleeding history:

APTT: prolonged
APTT results on a 1:1 mixture of the patient’s plasma
with normal plasma:
Preincubation: prolonged APTT
2-hour incubation: prolonged APTT

These results are consistent with:
A. Factor VIII deficiency
B. Factor VIII inhibitor
C. Lupus anticoagulant
D. Protein C deficiency

A

C. Lupus anticoagulant

44
Q
  1. Which test may be used to monitor LMWH
    therapy?
    A. APTT
    B. INR
    C. Anti-Xa heparin assay
    D. Activated clotting time
A

C. Anti-Xa heparin assay

***Medical Lab science review- Robert Harr 4th (63 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions